arrow_back Civic Audit
Share share

Boosting Research Funding for Charcot-Marie-Tooth Disease and Rare Disorders

This resolution highlights the impact of CMT disease and calls for increased federal funding for medical research. It aims to accelerate the discovery of treatments for thousands of affected individuals.
Key points
Recognizes CMT as a significant health issue affecting millions of people worldwide.
Urges robust funding for the National Institute of Neurological Disorders and Stroke to study the disease.
Emphasizes the need for continued investment in finding cures for rare diseases that currently have no treatment.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HRES_1079
Sponsor: Rep. Gottheimer, Josh [D-NJ-5]
Process start date: 2026-02-25
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Recognizing the significance of Charcot-Marie-Tooth disease and the need for robust funding of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HRES_1079.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-02-25.

What are the main provisions?

Key points include:

  • Recognizes CMT as a significant health issue affecting millions of people worldwide.
  • Urges robust funding for the National Institute of Neurological Disorders and Stroke to study the disease.
  • Emphasizes the need for continued investment in finding cures for rare diseases that currently have no treatment.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gottheimer, Josh [D-NJ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-02-26.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health